A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|DRUG: Sorafenib (Nexavar)
Sponsor: Veeda Oncology
Collaborators: Bayer|Celgene Corporation